Table 2.

Risk analyses for ESRD and doubling of serum creatinine according to plasma TNFSF13 levels

		Model One		Model Two		Model Three
Group	Outcome	HR (95% CI)	P Value	HR (95% CI)	P Value	HR (95% CI)	P Value
Undetectable (n=128)	ESRD	1 (reference)		1 (reference)		1 (reference)
First tertile (n=94)		2.86 (0.297 to 27.632)	0.36	3.87 (0.393 to 38.147)	0.25	4.52 (0.395 to 51.635)	0.23
Second tertile (n=94)		5.86 (0.684 to 50.199)	0.11	6.60 (0.751 to 57.933)	0.09	6.974 (0.665 to 73.188)	0.17
Third tertile (n=94)		28.65 (3.835 to 214.076)	0.001	9.47 (1.176 to 76.315)	0.04	10.67 (1.129 to 100.770)	0.04
Undetectable (n=128)	DCr	1 (reference)		1 (reference)		1 (reference)
First tertile (n=94)		1.42 (0.315 to 6.347)	0.65	1.87 (0.407 to 8.623)	0.42	2.20 (0.465 to 10.350)	0.32
Second tertile (n=94)		2.00 (0.478 to 8.389)	0.34	2.29 (0.531 to 9.886)	0.27	2.38 (0.599 to 13.167)	0.26
Third tertile (n=94)		11.97 (3.591 to 39.871)	<0.001	5.21 (1.428 to 19.034)	0.01	5.31 (1.377 to 20.464)	0.01

Model one: unadjusted for covariates.

Model two: adjusted for age, sex, baseline creatinine, proteinuria, and hematuria.

Model three: adjusted for covariates in model one plus smoking, hypertension, diabetes, autoimmune disease, hepatitis B antigen, anti-hepatitis C antibody, and the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or steroids.

HR, hazard ratio; 95% CI, confidence interval; DCr, doubling of serum creatinine.